On September 8, 2016, the Board instituted an IPR of U.S. Patent No. 6,331,415, one of the Cabilly patents owned by Genentech. The Petitioner in IPR2016-00710 is Mylan. The ’415 patent was the subject of two other IPRS that were terminated last week following settlements between Genentech and those Petitioners, Sanofi-Aventis and Genzyme, as we reported. The institution decision in the ’710 IPR and all other important IPR documents on biologic patents are posted on our IPR tracker page.
Blog Big Molecule Watch September 12, 2016